|
TRMT61B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.22044604925031E-16 |
| Normal-vs-Stage2 |
2.58410000064657E-08 |
| Normal-vs-Stage3 |
4.44089209850063E-16 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
8.312800E-01 |
| Stage1-vs-Stage3 |
2.560100E-02 |
| Stage1-vs-Stage4 |
1.218760E-04 |
| Stage2-vs-Stage3 |
1.052840E-01 |
| Stage2-vs-Stage4 |
1.975940E-03 |
| Stage3-vs-Stage4 |
5.386200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
7.28460000098963E-08 |
| Normal-vs-Asian |
1.21440000000472E-06 |
| Caucasian-vs-AfricanAmerican |
8.851000E-01 |
| Caucasian-vs-Asian |
1.323710E-02 |
| AfricanAmerican-vs-Asian |
1.449560E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
6.632200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62492241884138E-12 |
| Normal-vs-Age(41-60Yrs) |
1.88737914186277E-15 |
| Normal-vs-Age(61-80Yrs) |
1.62847513252018E-12 |
| Normal-vs-Age(81-100Yrs) |
9.416400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.836400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.529410E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.617400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.434800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.651200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.757600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.198200E-03 |
| Classical-VS-Follicular |
7.395000E-01 |
| Classical-VS-Other |
6.825400E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.383690E-02 |
| Tall-VS-Other |
4.446400E-01 |
| Tall-VS-Normal |
1.64535052249448E-13 |
| Follicular-VS-Other |
6.511800E-01 |
| Follicular-VS-Normal |
1.72310055113201E-10 |
| Other-VS-Normal |
1.041090E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.66133814775094E-16 |
| Normal-vs-N1 |
1.65645275274073E-13 |
| N0-vs-N1 |
6.660000E-02 |
|
|
